Drug intelligence / Profile preview

SBRX3

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX3 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of diabetes. It is part of the company's SBRX series of botanical therapeutics, which are derived from a proprietary database of medicinal plants. The drug is specifically designed to promote endogenous insulin production to help regulate blood glucose levels. SBRX3 is currently in the early stages of development, and while it is positioned as a pharmaceutical candidate, specific clinical trial data and molecular targets have not yet been publicly disclosed.

Beyond the preview

Go deeper on SBRX3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX3.

Explore the full profile